Anandamide, a naturally-occurring agonist of the cannabinoid receptor, blocks adenylate cyclase at the frog neuromuscular junction

21Citations
Citations of this article
3Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Anandamide (arachydonylethanolamide) is a naturally-occurring ligand of the cannabinoid receptor. When anandamide binds to its receptor, adenylate cyclase is inhibited. At the frog neuromuscular junction, anandamide lessened the increase in quantal size produced by pretreatment in hypertonic solution. It did not alter the increases in quantal size produced by insulin or by a permeable agonist of cAMP. It was known that hypertonic treatment increases quantal size by way of the cAMP-protein kinase A pathway. Anandamide had no effect on miniature endplate potential frequency (fmepp) in untreated preparations. After fmeppwas increased in the presence of a permeable cAMP agonist, anandamide brought fmeppback to resting levels. The conclusions are that the motor nerve terminal has a cannabinoid receptor. The binding of anandamide to this receptor seems to block adenylate cyclase. © 1994.

Cite

CITATION STYLE

APA

Van der Kloot, W. (1994). Anandamide, a naturally-occurring agonist of the cannabinoid receptor, blocks adenylate cyclase at the frog neuromuscular junction. Brain Research, 649(1–2), 181–184. https://doi.org/10.1016/0006-8993(94)91062-6

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free